London, United Kingdom, May 17th, 2022- Leading specialist market access consultancy Partners4Access have been selected as winners of ‘’Analyst Team of the Year 2022’’ by BHBIA BOBI Awards. The analyst team consisted of Andrea Bernardini, PhD, Nadia Al-lahiq, Olivia Johns, Fisentzos Stylianou, PhD & Adama Anozie.
The award ceremony took place in London at BHBIA 2022 conference on 16th May 2022, where the winners were announced.
Here’s what our analysts had to say after the announcement ‘’We would like to thank the BHBIA for this award and for giving us the opportunity second year in a row to take part in such exciting challenge. It was a long day full of brainstorming, teamwork powered by chocolate, and we are glad that it has paid off”.
Our amazing analysts took part in the ‘Analyst Team of the Year’ competition on 23rd March 2022. They were set the task at 07:30, followed by a Zoom briefing and had to commit to completing the task in a single day.
This year’s brief was a product launch scenario. The team had to identify opportunities for rapid uptake and sustained growth of a new product and illustrate their recommendations in the form of an infographic, spreadsheet, or interactive dashboard.
We faced tough competition in our category from: Novartis, Takeda, Catalyst Biosciences & Initiate Consultancy.
Well done to all the finalists, we are over the moon to have won!
About Partners4Access:
P4A are specialists 100% focused on cell & gene therapy and orphan drug access, partnering with the biotechnology industry to support launches worldwide. Focus areas include CGT & orphan drugs pricing and market access strategy; bespoke access roadmap; rare disease foresights; evidence optimisation solutions; access team excellence. As one of the only consultancies with comprehensive experience in cell and gene therapies, P4A are excellently placed to help clients successfully achieve access.
Through its initiatives, P4A are able to inform and shape the conversation around CGT & orphan drugs.
The team at P4A believe in striking an equilibrium in the rare disease world. That means helping drive access to the most appropriate treatments for patients and physicians, a fair return on investment for manufacturers at an affordable proposition for payers.
For more information, please email P4A at [email protected].
About the BHBIA:
Established over 60 years ago to provide members with on-going learning & development that will help them perform their professional role in the workplace. BHBIA runs a comprehensive program of activities throughout the year to help develop the skills of those working in the pharma, biotech & healthcare consultancies
Their members are drawn from pharmaceutical/ healthcare companies and the agencies/ consultancies that supply business intelligence services to those companies. Their definition of ‘business intelligence services’ includes primary market research, secondary data collection and analysis, syndicated data services, field force effectiveness services and fieldwork recruiting.
For more information, please go to www.bhbia.org.uk
